Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)

 Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)

Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)

Shots:

  • Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim
  • The focus of the agreement is to discover & develop GPCRs, using Domain’s DTect-All and bioSens-All technology to characterize compounds for Neuropsychiatric Diseases
  • GPCRs are receptors present in CNS, activates by binding with stimulus or ligand and regulates the functions of brain

Click here to read full press release/ article | Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post